ALKBH5 and ovarian carcinoma: Additionally, dysregulation of ALKBH5 was found to mediate drug- or radio-resistance in GBM [85, 158], oral squamous cell carcinoma [112], bladder cancer [114], pancreatic cancer [121] and BRCA-mutated epithelial ovarian cancers [159] (Table 3).